Published Study Found Underlying Tremor Improvement with Consistent use of Cala TAPS Therapy in Patients with Essential Tremor

SAN MATEO, Calif., Feb. 9, 2026 /PRNewswire/ — Cala®, the bioelectronic medicine leader, today announced publication of a retrospective analysis of the multicenter PROSPECT trial of TAPS® therapy, in the peer-reviewed journal, Tremor and Other Hyperkinetic Movements.  The study assessed underlying tremor improvement in essential tremor (ET) patients, evaluated after months of consistent use of TAPS therapy, which is differentiated from acute or lasting effect measured during stimulation and in the minutes/hours after the stimulation session, respectively.  The analysis found tremor severity reduction in pre-stimulation measurements at one- and three-month follow-up visits, suggesting regular use of Cala TAPS® therapy may confer sustained therapeutic benefit.